General Use

Used in the treatment of reversible airway obstruction due to asthma or chronic obstructive pulmonary disease (COPD). Recommendations for management of asthma recommend that rapid-acting inhaled beta-agonist bronchodilators (not salmeterol, formoterol, arformoterol, indacaterol, olodaterol, or vilanterol) be reserved as acute relievers of bronchospasm; repeated or chronic use indicates the need for additional long-term control agents, including inhaled corticosteroids, mast cell stabilizers, long-acting bronchodilators (oral theophylline, beta₂-agonists, or anticholinergics), and leukotriene modifiers (montelukast, zafirlukast).